To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
News | Article | Biotechnology | Pharmacology
Deeptope, founded in February 2021 from a technology developed at the DMTS Laboratory of Cellular Immunology and Biotechnology (LICB), is a company of therapeutic antibody engineering that provides antibody optimization and characterization services to biotech or pharmaceutical firms with the goal of increasing the quality of antibodies in a very short timeframe.
Therapeutic antibodies are antibodies produced by cells in culture to treat specific diseases. More than 30 monoclonal antibodies are marketed in France today for the treatment of chronic inflammatory diseases, cancers, transplant rejection and, more recently, in the fight against SARS-CoV-2 infection. Deeptope uses a combination of technologies of Yeast Surface Display (YSD) coupled with flow cytometric cell sorting and high-throughput sequencing. This approach allows to i) replace each amino acid of a sequence (either an antibody or an antigen) by the 20 other amino acids and thus identify the residues involved in antigen/antibody (Ag/Ab) recognition; ii) express all the variants (each mono-mutant); iii) functionally correlate the impact of each mutation on the Ag/Ab interaction. The data produced allows the fine characterization of antibody binding modes in a very short time (4 to 6 weeks), i.e. the mapping of epitopes (recognition zone on the antigen) and paratopes (amino acids of the antibody involved in the interaction). These data are then used to select mutations in order to optimize the functional properties of the antibodies in terms of affinity, selectivity, cross-reactivity between species, humanization, de-immunization, specificity, selectivity and stability. Contacts : Raphaël Sierocki (co-founder, scientific director) firstname.lastname@example.org ; Bernard Maillère (head of the LICB laboratory at CEA) email@example.com The Laboratory of Cellular Immunology and Biotechnology (LICB/SIMoS/DMTS) of the Joliot Institute has made research on the mechanisms of immunogenicity and the optimization of therapeutic antibodies its main area of expertise, with the aim of producing effective and low immunogenic antibodies. It is directed by Bernard Maillère. Raphaël Sierocki defended in January 2020 his PhD thesis from the Paris-Saclay University entitled "Design and characterization of non-immunogenic antibodies: application to an anti-Salmonella/Shigella antibody", which he performed under the supervision of Hervé Nozac'h (team leader at the LICB), Bernard Maillère (head of the LICB/DMTS) and Stéphanie Simon (head of the LERI/DMTS).
To learn more on Deeptope : https://deeptope.com/
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.